The Problem

Heart Failure is on the Rise

Heart failure has reached epidemic proportions in the United States, affecting an estimated 6.5 million patients in 2014* at a cost of $30.7B annually—projected to reach $69.7B in 2030.

To make matters worse, heart failure patients can also suffer from co-morbidities such as sleep disorder breathing (SDB), leading to poor outcomes as their heart failure symptoms and conditions deteriorate. 

Co-morbidities Worsen Heart Failure Symptoms

In fact, 74% of heart failure patients experience Central Sleep Apnea (CSA), Obstructive Sleep Apnea (OSA), or  both—which can significantly worsen heart failure conditions.

One Device, Two Co-mordibities

The RMx Solution Treats Both CSA and OSA

Using phrenic nerve/diaphragm stimulation, we’re working to make better outcomes possible for heart failure patients experiencing the negative effects of CSA and OSA. With just one device, the RMx solution can treat two comorbidities in a single patient by minimizing hypoxia and arousals to reduce stress on the heart.

And, we own a substantial IP portfolio of phrenic nerve and diaphragm stimulation patents and published human clinical evidence demonstrating treatment safety and efficacy. 

Our goal? To develop a fully-featured product promoting improved clinical outcomes at a lower procedure cost.



Connect with us for more information about the RMx solution.